Categories AlphaGraphs, Earnings, LATEST, Other Industries

Honeywell beats earnings estimates; revises guidance

Honeywell International (HON) reported third-quarter 2018 sales that came in line with analysts’ expectations and earnings that topped estimates. After climbing as much as 3.2% during premarket hours on Friday, the stock is currently up around 2.9%.

Total sales grew 6% to $10.7 billion from the same period last year. Organic sales grew 7%, driven by growth in the Aerospace business, warehouse automation business and momentum in Homes and ADI global distribution.

Honeywell third quarter 2018 Earnings Infographic
Honeywell Q3 2018 Earnings Infographic

Net income attributable to Honeywell grew to $2.3 billion or $3.11 per share from $1.3 billion or $1.74 per share in the prior-year period. Reported earnings included separation costs related to the Garrett and Resideo spinoffs as well as a favorable adjustment to US tax legislation-related charges incurred in Q4 2017. Adjusted EPS grew 17% to $2.03.

Segment margin expanded 70 basis points, 20 basis points above the high end of the company’s guidance, driven by higher volumes and operational excellence initiatives.

Honeywell posted sales increases across all its operating segments. Aerospace benefited from strong demand from business aviation OEMs, strength in the domestic and international defense business and growth in the air transport and business aviation aftermarket.

Home and Building Technologies saw growth driven by strength in the ADI Global Distribution and Building Solutions businesses as well as demand for commercial fire products and residential thermal solutions.

Sales growth in the Performance Materials and Technologies division was driven by demand for products and services in the Advanced Materials and Process Solutions businesses as well as engineering sales growth in UOP.

In Safety and Productivity Solutions, the growth in sales was helped by double-digit sales growth in the Intelligrated business, strong demand for new mobility solutions and higher sensing and industrial safety volumes.

Earnings Preview: Higher expenses to weigh on Honeywell’s Q3

Honeywell revised its guidance for the full year of 2018 to reflect the strong operational performance year-to-date and the spinoffs of Garrett Motion and Resideo Technologies.

The company now expects sales of $41.7 billion to $41.8 billion and adjusted EPS of $7.95 to $8.00. This compares to the previous outlook for sales of $43.1 billion to $43.6 billion and for adjusted EPS of $8.10 to $8.20. Organic sales growth is expected to be approx. 6% and segment margin expansion is expected to be 50-60 basis points.

Honeywell completed the spinoff of Garrett Motion Inc. on October 1 and expects to complete the Resideo Technologies spinoff on October 29. The company also announced its plans to acquire warehouse automation solutions provider Transnorm for EUR425 million. The transaction is expected to close in November.

During the quarter, the company repurchased approx. $600 million in shares and increased its dividend by 10%.

 

Listen to publicly listed companies’ earnings conference calls along with the edited closed caption text.

Most Popular

Microsoft (MSFT) reports higher revenue and profit for Q3 2024

Microsoft Corp. (NASDAQ: MSFT) on Thursday said its third-quarter 2024 earnings increased year-over-year, reflecting strong performance by the tech giant’s main operating segments. Third-quarter revenues came in at $61.86 billion,

GOOG, GOOGL Earnings: All you need to know about Alphabet’s Q1 2024 earnings results

Alphabet Inc. (NASDAQ: GOOG, GOOGL) reported its first quarter 2024 earnings results today. Revenues increased 15% year-over-year to $80.5 billion. Revenue growth was 16% in constant currency. Net income was

MRK Earnings: Merck Q1 2024 profit jumps on 9% revenue growth

Pharmaceutical company Merck & Co. Inc. (NYSE: MRK) reported a sharp increase in adjusted earnings for the first quarter of 2024, aided by an increase in revenues. First-quarter worldwide sales

Tags

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top